表 6.
阿替利珠单抗单药组的不良事件
Adverse events in the atezolizumab monotherapy arm
| Items | Atezolizumaba (n=100) | Items | Atezolizumaba (n=100) | |
| AE, adverse event. a, percentages are based on n in the column heading. For frequency counts by preferred term, multiple occurrences of the same AE in an individual are counted only once. | ||||
| AEs (≥10%), n(%) | 98 (98.0) | AEs leading to treatment discontinuation, n(%) | 17 (17.0) | |
| Aspartate aminotransferase increased | 30 (30.0) | Hepatic function abnormal | 3 (3.0) | |
| Anemia | 29 (29.0) | Death | 2 (2.0) | |
| Pyrexia | 28 (28.0) | Dyspnea | 2 (2.0) | |
| Alanine aminotransferase increased | 26 (26.0) | Aspartate aminotransferase increased | 1 (1.0) | |
| Decreased appetite | 24 (24.0) | Blood creatinine phosphokinase increased | 1 (1.0) | |
| Fatigue | 24 (24.0) | Esophagobronchial fistula | 1 (1.0) | |
| Blood bilirubin increased | 24 (24.0) | Fistula | 1 (1.0) | |
| White blood cell count decreased | 22 (22.0) | Hyponatremia | 1 (1.0) | |
| Neutrophil count decreased | 16 (16.0) | Neoplasm progression | 1 (1.0) | |
| Bilirubin conjugated increased | 15 (15.0) | Pneumonia fungal | 1 (1.0) | |
| Hyponatremia | 13 (13.0) | Polymyositis | 1 (1.0) | |
| Weight decreased | 13 (13.0) | Sudden death | 1 (1.0) | |
| Proteinuria | 13 (13.0) | Transaminases increased | 1 (1.0) | |
| Upper respiratory tract infection | 13 (13.0) | |||
| Nausea | 11 (11.0) | |||
| Hypoalbuminemia | 10 (10.0) | |||